A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Male and Non-Fertile Female, Young and Elderly Healthy Volunteers, After Oral Multiple Ascending Doses
Latest Information Update: 18 Jan 2010
At a glance
- Drugs AZD 1446 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 01 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 May 2009 New trial record